Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Riboflavin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.74 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 7/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.87 |
| ▸ | USP2 | O75604 | 4/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.87 |
| ▸ | HAT1 | O14929 | 4/20 | 0.87 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.87 |
| ▸ | HTT | P42858 | 4/20 | 0.87 |
| ▸ | RECQL | P46063 | 3/20 | 0.87 |
| ▸ | CASP7 | P55210 | 3/20 | 0.87 |
| ▸ | MAPT | P10636 | 3/20 | 0.87 |
| ▸ | CASP1 | P29466 | 2/20 | 0.87 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.87 |
| ▸ | TST | Q16762 | 2/20 | 0.87 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | HBB | P68871 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riboflavin SCHEMBL50154 | 1.00 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL27866166 | 1.00 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL367680 | 0.99 | MEN1 (0.85) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL1085508 | 0.98 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL296802 | 0.97 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL21805317 | 0.97 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL618997 | 0.97 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL367681 | 0.96 | MEN1 (0.87) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL2241206 | 0.95 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 | |
| Riboflavin SCHEMBL1085509 | 0.95 | MEN1 (0.89) | MEN1KMT2AUSP2KDM4EHAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111094309-A | Preparation method of high-purity riboflavin sodium phosphate | 邦泰生物工程(深圳)有限公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-2415473-B1 | ORAL CARE COMPOSITIONS CONTAINING COMBINATIONS OF ANTI-BACTERIAL AND HOST-RESPONSE MODULATING AGENTS | PROCTER & GAMBLE (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8283135-B2 | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2079468-B1 | ORAL CARE COMPOSITIONS CONTAINING COMBINATIONS OF ANTI-BACTERIAL AND HOST-RESPONSE MODULATING AGENTS | PROCTER & GAMBLE (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2415473-A1 | Oral Care Compositions Containing Combinations of Anti-Bacterial and Host-Response Modulating Agents | The Procter & Gamble Company (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-2079468-A1 | ORAL CARE COMPOSITIONS CONTAINING COMBINATIONS OF ANTI-BACTERIAL AND HOST-RESPONSE MODULATING AGENTS | The Procter and Gamble Company (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008057136-A1 | ORAL CARE COMPOSITIONS CONTAINING COMBINATIONS OF ANTI-BACTERIAL AND HOST-RESPONSE MODULATING AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20070053849-A1 | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents | THE PROCTER & GAMBLE COMPANY | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070053849-A1 | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents | TLR5, LTA, TLR3 | ADRB2 4246/4885ADRA1A 4219/4885MEN1 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.